Health Condition 1: E283- Primary ovarian failure
Conditions
Interventions
Intervention1: Satawar (Asparagus racemosus): Formulation Type: Safoof (fine powder)
Dosage: 6 grams (3 gms in the morning, 3 gms in the evening)
Adjuvant: To be taken with lukewarm milk
Route: Oral
Sponsors
Dr Umme Aman Saba
Eligibility
Inclusion criteria
Inclusion criteria: Female patients aged between 20 and 40 years. Serum amh levels below 1.0 ng/mL. Regular menstrual cycle or oligo/irregular cycles. Patients with Amenorrhea. Infertile patients. Willing to participate and sign the written informed consent. Fit to take oral Unani medications for the duration of the study.
Exclusion criteria
Exclusion criteria: Known systemic disorders such as tuberculosis, or malignancy. Menopause women s. Women with comorbidities. Patients undergoing assisted reproductive technologies (ART) concurrently. Pregnant or lactating women. Hypersensitivity to the drug Administration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Elevated Serum Anti-M llerian Hormone (AMH) LevelsTimepoint: Baseline (Day 0) End of treatment Day 90 ( 3 days) | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in menstrual regularity and flow pattern Change in Antral Follicle Count (AFC) Change in ovarian volume Absence of adverse drug reactions and assessment of safetyTimepoint: Menstrual pattern: Assessed monthly during treatment and at Day 90 Antral Follicle Count (AFC): Assessed at baseline (Day 0) and Day 90 Ovarian volume: Assessed at baseline (Day 0) and Day 90 Safety parameters and adverse events: Monitored throughout the study period | — |
Countries
India
Contacts
Public ContactDr Syeda Abidunnisa
Government Nizamia Tibbi College And General Hospital
Outcome results
None listed